ClinicalTrials.gg
RecruitingNCT07365904Updated Jan 26, 2026

Investigating Ovulation Inhibition for Use as a Contraceptive

A Phase 2 interventional study of MR-130A-01 contraceptive transdermal patch, containing norelgestromin (NGMN) in Contraception, sponsored by Mylan Pharmaceuticals Inc. Recruiting at 1 site in Germany. Open to female participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-26.

Sponsored by Mylan Pharmaceuticals Inc (part of Viatris Inc.) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
Female
01

Study summary

A single-centre, open-label, randomised, phase II study on the maintenance of ovulation inhibition after intentional application errors during 84 days of treatment with MR 130A 01 contraceptive transdermal patch

Read the detailed description

Ovulation inhibition study of MR-130A-01 contraceptive transdermal patch containing norelgestromin with intentional application errors; MR-130A-01-TD-2002

02

Conditions studied

  • Contraception
03

In context

Lead sponsor

Mylan Pharmaceuticals Inc is the lead sponsor of 160 studies on the registry; 1 is open to participants now.

First submitted after Mylan Pharmaceuticals Inc became part of Viatris Inc..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Healthy, post-menarcheal and premenopausal women of age 18 to 35 years (inclusive) at screening examination.

    2. ≥18.0 kg/m2 at screening examination. 3. Participants must be in good physical and mental health as determined by vital signs, medical history, and physical and gynecological examination, as assessed by the investigator.

    4. Written , after having been informed about benefits and potential risks of the clinical trial, as well as details of the insurance taken out to cover the participant participating in the clinical trial.

    5. Status at least 3 months after a delivery, abortion, and stopping lactation, if applicable, before screening.

    6. Has regular menstrual cycles that are between 21 and 35 days in duration as reported by the participant during anamnesis, with an intact uterus and ovaries. If the participant uses hormonal at screening, historic data should be used to evaluate this criterion.

    7. Both ovaries must be visible on TVUS examination during screening. 8. Ovulatory pre-treatment cycle, as confirmed by a progesterone concentration >10.0 nmol/L.

    9. Participants must consent to use reliable non-hormonal contraceptive methods (male condoms, diaphragm, or heterosexual abstinence) throughout the study, unless the participant has a history of female sterilization or sterilization of the sexual partner.

Exclusion criteria

Exclusion Criteria:

  • 1. Known or intolerance to any ingredient of the product.

    2. History or presence of dermal sensitivity to medicated patches or to topical applications including bandages, surgical tape.

    3. Pregnancy or a positive serum beta human chorionic gonadotropin (β-hCG) pregnancy test at screening.

    4. abnormal findings from serum biochemistry and hematology and HBsAG/ virus/ (HIV) serology as evaluated by the investigator 5. ASAT (aspartate-aminotransferase) > 20 % (ULN), ALAT (alanine-aminotransferase) > 10 % ULN, > 20% ULN (except in case of existing Morbus Gilbert-Meulengracht deduced from anamnesis/medical history) and creatinine > 0.1 mg/dL ULN (limit of > 0.1 mg/dL corresponds to > 9 µmol/l ULN).

    6. Use of a non-hormonal intra-uterine device within the pre-treatment cycle or any hormonal as follows:

    • Short-acting hormonal contraceptives such as oral, patch, ring or intrauterine systems within the menstrual cycle prior to the pre-treatment cycle.
    • Injectable (intramuscularly or subcutaneously) within 10 months (three-month treatment duration), 6 months (two-month treatment duration) or 3 months (one-month treatment duration) prior to the start of pre-treatment cycle or implants within the menstrual cycle prior to the pre-treatment cycle.

      7. Known or suspected or history thereof. 8. Unexplained vaginal bleeding within the past 6 months suspicious for serious condition, or any abnormal bleeding which is expected to recur during the study (e.g. bleeding from cervical polyp, recurrent bleeding after sex).

      9. History or presence of ischemic heart disease, coronary artery disease, myocardial infarction, stroke, other cerebrovascular diseases including (TIAs).

      10. History or presence of hypertension or hypertension with vascular disease or elevated blood pressure (BP) defined as systolic BP ≥140 mm Hg or diastolic BP ≥90 mm Hg, measured in sitting position after at least 5 minutes of rest (a single reading of blood pressure level is not sufficient to classify a woman as hypertensive).

      11. Pulse rate (PR) \< 50 bpm or > 90 bpm 12. Presence of deep vein thrombosis/pulmonary embolism. 13. Has any comorbid condition that may require major surgery with prolonged immobilization during the study period.

      14. Presence of liver disease including severe (decompensated) cirrhosis, benign (e.g., hepatocellular adenoma) or malignant liver tumors.

      15. Chronic disease potentially necessitating organ transplantation during the anticipated course of the study.

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    "regular": regular application without planned application errors

    Drug: MR-130A-01 contraceptive transdermal patch, containing norelgestromin (NGMN)

  • Experimental
    Extended Period 1: regular application with planned application errors

    Drug: MR-130A-01 contraceptive transdermal patch, containing norelgestromin (NGMN)

  • Experimental
    Extended Period 2: regular application with planned application errors

    Drug: MR-130A-01 contraceptive transdermal patch, containing norelgestromin (NGMN)

Interventions

  • DrugMR-130A-01 contraceptive transdermal patch, containing norelgestromin (NGMN)

    MR-130A-01 contraceptive transdermal patch, containing norelgestromin (NGMN)

06

What researchers measure

Primary outcomes

  1. Ovulation incidence in cycle with regular application, and in cycles with extended period application errors. Ovulation is defined as a Hoogland-Skouby score 5 or 6 in combination with fulfilment of Landgren criterion.

    Time frame: 84 days

Secondary outcomes

  1. Ovulation incidence overall and incidence per treatment cycle.

    Time frame: 84 days

  2. HSS determined for each treatment cycle.

    Time frame: 84 days

  3. Fulfilment of Landgren criterion in cycles with HSS 5 or 6.

    Time frame: 84 days

  4. FLS diameter and endometrial thickness determined by transvaginal ultrasound (TVUS).

    Time frame: 84 days

  5. Pituitary (luteinizing hormone [LH]) and ovarian (estradiol [E2], progesterone [P]) hormone concentrations in serum.

    Time frame: 84 days

  6. Plasma concentration of NGMN and its metabolite norgestrel Immediately 5min before and at the end of one scheduled patch-free window.

    Time frame: 84 days

  7. Plasma concentrations of NGMN and norgestrel.

    Time frame: 84 days

  8. Assessment of adhesion score by the participants themselves and by the site personnel.

    Time frame: 84 days

  9. Safety and tolerability: Treatment-emergent Adverse Events (TEAE) Safety clinical laboratory parameters Incidence of application site reactions (skin irritation scores assessed by the participants).

    Time frame: 84 days

  10. Bleeding pattern determined as Incidences of bleeding and/or spotting episodes. Number of observed days of bleeding and/or spotting, bleeding only and spotting only. Incidences of complete absence of bleeding or spotting (excluding the first episode).

    Time frame: 84 days

07

Study locations

1 of 1 sites recruiting
  • dinox GmbH
    Berlin, Germany
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for Nov 2026, 11 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2025
First posted
Jan 26, 2026
StartActual
Dec 22, 2025
Primary completionEst.
Nov 30, 2026
CompletionEst.
Nov 30, 2026
Last update
Jan 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07365904
Responsible party
Sponsor
First posted
Jan 26, 2026
Start date
Dec 22, 2025
Primary completion
Nov 30, 2026 (estimated)
Completion
Nov 30, 2026 (estimated)
Last update
Jan 26, 2026

Study contacts

Erin R Larnerd
Contact
erin.larnerd@viatris.com
3045545844
Laura F Zachwieja
Contact
laura.zachwieja@viatris.com
304-680-0256
Sandeep Jagtap
study director · Meda Pharma GmbH & Co. KG (a Viatris company)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion